HRP20151182T1 - Kolagenaza za tretiranje celulita - Google Patents

Kolagenaza za tretiranje celulita Download PDF

Info

Publication number
HRP20151182T1
HRP20151182T1 HRP20151182TT HRP20151182T HRP20151182T1 HR P20151182 T1 HRP20151182 T1 HR P20151182T1 HR P20151182T T HRP20151182T T HR P20151182TT HR P20151182 T HRP20151182 T HR P20151182T HR P20151182 T1 HRP20151182 T1 HR P20151182T1
Authority
HR
Croatia
Prior art keywords
collagenase
purified
purified collagenase
injected
administered
Prior art date
Application number
HRP20151182TT
Other languages
English (en)
Inventor
Marie A. Badalemente
Alexander B. Dagum
Original Assignee
The Research Foundation For The State University Of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Research Foundation For The State University Of New York filed Critical The Research Foundation For The State University Of New York
Publication of HRP20151182T1 publication Critical patent/HRP20151182T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66Enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886Metalloendopeptidases (3.4.24), e.g. collagenase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61QSPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00Preparations for care of the skin
    • A61Q19/06Preparations for care of the skin for countering cellulitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/20Chemical, physico-chemical or functional or structural properties of the composition as a whole
    • A61K2800/30Characterized by the absence of a particular group of ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)

Claims (7)

1. Pročišćena kolagenaza za primjenu u terapiji celulita kod ljudi, administriranjem u potkožnu kolagenu mrežu, naznačena time što je kolagenza u biti pročišćena od drugih enzima, pri čemu se pročišćena kolagenaza ubrizgava u dozi od najmanje 1 000 ABC jedinica, primjenjenoj u vidu jedne ili više injekcija i naznačena time što je kolagenaza pročišćena iz bakterije Clostridium histolyticum.
2. Pročišćena kolagenaza za primjenu kao u zahtjevu 1, naznačena time što se pročišćena kolagenaza primjenjuje bez triamcinolona ili nekog drugog kortikosteroida.
3. Pročišćena kolagenaza za primjenu kao u zahtjevu 1, naznačena time što se pročišćena kolagenaza ubrizgava u volumenu od 1.0 ml.
4. Pročišćena kolagenaza za primjenu kao u zahtjevu 1, naznačena time što se pročišćena kolagenaza ubrizgava na različitim mjestima.
5. Pročišćena kolagenaza za primjenu kao u zahtjevu 1, naznačena time što se pročišćena kolagenaza sastoji od od kolagenaze I i kolagenaze II.
6. Pročišćena kolagenaza kao u zahtjevu 1, naznačena time što se tretman ponavlja nakon četiri do šest mjeseci.
7. Pročišćena kolagenaza za primjenu kao u zahtjevu 5, naznačena time što se pročišćena kolagenaza administrira u farmaceutski prihvatljivom tekućem nosaču i sastoji se od kolagenaze I i kolagenaze II u odnosu masa 1 prema 1.
HRP20151182TT 2006-02-22 2015-11-04 Kolagenaza za tretiranje celulita HRP20151182T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77569006P 2006-02-22 2006-02-22
US11/703,269 US20070224184A1 (en) 2006-02-22 2007-02-07 Method for treating cellulite
PCT/US2007/004752 WO2007100675A2 (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite
EP07751508.8A EP1991258B1 (en) 2006-02-22 2007-02-22 Collagenase for treating cellulite

Publications (1)

Publication Number Publication Date
HRP20151182T1 true HRP20151182T1 (hr) 2016-01-01

Family

ID=38325147

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20151182TT HRP20151182T1 (hr) 2006-02-22 2015-11-04 Kolagenaza za tretiranje celulita

Country Status (19)

Country Link
US (4) US20070224184A1 (hr)
EP (1) EP1991258B1 (hr)
JP (5) JP5775658B2 (hr)
KR (2) KR20080108996A (hr)
AU (1) AU2007221225B2 (hr)
BR (1) BRPI0708186A2 (hr)
CA (1) CA2643171C (hr)
DK (1) DK1991258T3 (hr)
ES (1) ES2553184T3 (hr)
HR (1) HRP20151182T1 (hr)
HU (1) HUE025918T2 (hr)
IL (1) IL193639A (hr)
MX (1) MX2008010767A (hr)
NZ (1) NZ570642A (hr)
PL (1) PL1991258T3 (hr)
PT (1) PT1991258E (hr)
RS (1) RS54372B1 (hr)
SI (1) SI1991258T1 (hr)
WO (1) WO2007100675A2 (hr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6958150B2 (en) 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
KR100989267B1 (ko) * 2005-01-21 2010-10-20 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 유착 관절낭염을 치료하는 방법
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US20090233885A1 (en) * 2006-07-14 2009-09-17 Duncan Diane I Compositions and Methods for Fat Reduction
US10071143B1 (en) 2007-05-03 2018-09-11 The Research Foundation For The State University Of New York Methods for non-surgical treatment of carpal tunnel syndrome
TWI395593B (zh) 2008-03-06 2013-05-11 Halozyme Inc 可活化的基質降解酵素之活體內暫時性控制
US20110229451A2 (en) * 2009-03-06 2011-09-22 Halozyme, Inc. Temperature sensitive mutants of matrix metalloproteases and uses thereof
JP5284239B2 (ja) * 2009-10-07 2013-09-11 株式会社メタコ スクリーン装置
FR2966734B1 (fr) * 2010-10-29 2014-07-18 Max Rombi Composition comprenant au moins une enzyme proteolytique pour son utilisation pour empecher la synthese des triglycerides
ES2953560T3 (es) * 2011-10-21 2023-11-14 Endo Global Ventures Procedimiento para el tratamiento o reducción de paniculopatía fibrosclerótica edematosa
NZ766918A (en) 2012-01-12 2023-03-31 Auxilium Int Holdings Inc Clostridium histolyticum enzymes and methods for the use thereof
US9636385B2 (en) 2012-10-24 2017-05-02 The Research Foundation For The State University Of New York Use of collagenase to treat glaucoma
WO2014107745A1 (en) 2013-01-07 2014-07-10 Halozyme, Inc. Metal sensitive mutants of matrix metalloproteases and uses thereof
EP3834840A1 (en) 2013-03-15 2021-06-16 BioSpecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
US10117892B2 (en) 2013-08-29 2018-11-06 Allergan, Inc. Devices and methods for reducing the appearance of cellulite
CN103751102A (zh) 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
US11123280B2 (en) 2017-03-01 2021-09-21 Endo Ventures Limited Method of assessing and treating cellulite
US11473074B2 (en) 2017-03-28 2022-10-18 Endo Global Aesthetics Limited Method of producing collagenase
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
CN113015514A (zh) * 2018-09-18 2021-06-22 恩多全球美学有限公司 用于治疗皮下脂肪团的组合物和方法
CN113382714A (zh) * 2019-01-06 2021-09-10 恩多全球美学有限公司 胶原酶制剂及其制备方法
CA3157517A1 (en) 2019-10-15 2021-04-22 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
BR112022010042A2 (pt) * 2019-11-26 2022-08-16 Standard Of Care Corp Composições de hialuronidase e métodos de uso da mesma para tratar celulite
WO2023218384A1 (en) * 2022-05-10 2023-11-16 Endo Global Aesthetics Limited Methods of reducing collagenase-mediated bruising in a subject having cellulite

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4338300A (en) * 1981-02-05 1982-07-06 The Regents Of The University Of California Use of purified clostridial collangenase in the treatment of Peyronie's disease
US4645668A (en) * 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US5393792A (en) * 1991-11-20 1995-02-28 Advance Biofactures Of Curacao, N.V. High dosage topical forms of collagenase
US5332503A (en) * 1993-04-16 1994-07-26 Baxter International Inc. Process for purifying collagenase
CA2189646C (en) * 1994-06-24 1999-05-25 Francis E. Dwulet A purified mixture of collagenases and two other proteases obtained from clostridium histolyticum
US5589171A (en) * 1994-08-22 1996-12-31 Advance Biofactures Of Curacao Treatment of Dupuytren's disease with collagenase
CA2158822C (en) * 1994-09-27 2008-12-23 Kusuki Nishioka Therapeutic agent for rheumatic disease
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
US5830741A (en) * 1996-12-06 1998-11-03 Boehringer Mannheim Corporation Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease
US6086872A (en) * 1997-03-27 2000-07-11 Advance Biofactures Of Curacao, Nv Amelioration of dupuytren's disease
WO1999017738A1 (en) * 1997-10-03 1999-04-15 Lavipharm Laboratories, Inc. A prolamine-plant polar lipid composition, its method of preparation and applications thereof
US6022539A (en) * 1999-06-03 2000-02-08 Advance Biofactures Of Curacao Amelioration of peyronie's disease
WO2001013865A1 (en) * 1999-08-20 2001-03-01 Howard Murad Pharmaceutical compositions and methods for reducing the appearance of cellulite
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
KR100989267B1 (ko) * 2005-01-21 2010-10-20 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 유착 관절낭염을 치료하는 방법
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases

Also Published As

Publication number Publication date
KR20080108996A (ko) 2008-12-16
MX2008010767A (es) 2008-09-01
JP2020015771A (ja) 2020-01-30
JP6853331B2 (ja) 2021-03-31
PT1991258E (pt) 2015-11-24
JP2009527570A (ja) 2009-07-30
HUE025918T2 (en) 2016-05-30
US20160279046A1 (en) 2016-09-29
WO2007100675A3 (en) 2007-11-15
SI1991258T1 (sl) 2016-02-29
US20190053995A1 (en) 2019-02-21
US10123959B2 (en) 2018-11-13
US20070224184A1 (en) 2007-09-27
NZ570642A (en) 2012-03-30
IL193639A (en) 2015-01-29
KR20120006063A (ko) 2012-01-17
CA2643171A1 (en) 2007-09-07
PL1991258T3 (pl) 2016-04-29
DK1991258T3 (en) 2015-11-16
EP1991258B1 (en) 2015-08-12
ES2553184T3 (es) 2015-12-04
JP2018199733A (ja) 2018-12-20
RS54372B1 (en) 2016-04-28
JP2015134840A (ja) 2015-07-27
JP6649449B2 (ja) 2020-02-19
AU2007221225A1 (en) 2007-09-07
EP1991258A2 (en) 2008-11-19
BRPI0708186A2 (pt) 2011-05-24
IL193639A0 (en) 2011-08-01
JP5775658B2 (ja) 2015-09-09
WO2007100675A2 (en) 2007-09-07
CA2643171C (en) 2018-10-02
US20220249348A1 (en) 2022-08-11
AU2007221225B2 (en) 2010-02-11
JP6498167B2 (ja) 2019-04-10
JP2016204396A (ja) 2016-12-08

Similar Documents

Publication Publication Date Title
HRP20151182T1 (hr) Kolagenaza za tretiranje celulita
JP2018199733A5 (hr)
JP2016204396A5 (hr)
ATE321529T1 (de) Dosierungsform für eine verzögerte und zunehmende wirkstoffsfreisetzung
IL171607A (en) Use of botulinum toxin for the treatment of sinusitis-induced headaches
MX337511B (es) Medicamentos y metodos para tratar cefaleas.
Garrido et al. Gonyautoxin: new treatment for healing acute and chronic anal fissures
HRP20110497T4 (hr) Postupci za primjenu kompozicija aminopiridina sa produženim oslobađanjem
RS52867B (en) GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
BRPI0513200A (pt) uso de um anticorpo anti-igf-1r na preparação de um medicamento para tratamento combinado para malignidades não-hematológicas
AR032349A1 (es) Uso de neurotoxinas para preparar composiciones farmaceuticas de aplicacion en el tratamiento de trastornos del movimiento
NZ703394A (en) Compositions and methods for treating crohn’s disease and related conditions and infections
WO2006039704A3 (en) Pharmaceutical composition and method for treating a joint capsule arthropathy
IS8187A (is) Meðferð á fráhvarfseinkennum
JP2007514749A5 (hr)
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
HRP20150889T1 (hr) Postupci za lijeäśenje adhezivnog kapsulitisa
WO2005055921A3 (en) Compositions for treatment of ear disorders and methods of use thereof
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
Shallenberger et al. Prolozone™–regenerating joints and eliminating pain
HRP20230300T1 (hr) Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije
GT200000071A (es) Nuevas combinaciones farmaceuticas para inhibidores de la nos.
JP2009534367A5 (hr)
DK1605890T3 (da) Kit til farmaceutisk anvendelse
DE69803670D1 (de) Tiagabinhaltige arzneizubereitungen mit gesteuerter wirkstoffverabreichung